TransMedics Group, Inc. (BIT:1TMDX)

Revenue Breakdown

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 28, 2019	Dec 29, 2018	Dec 30, 2017	Dec 31, 2016
United States Lung Revenue	13.44M	15.76M
United States Lung Revenue Growth	-14.67%	49.36%
United States Heart Revenue	111.84M	96.66M
United States Heart Revenue Growth	15.70%	63.61%
United States Liver Revenue	459.42M	309.46M
United States Liver Revenue Growth	48.46%	103.97%
United States OCS Transplant Revenue	584.70M	421.88M
United States OCS Transplant Revenue Growth	38.59%	90.60%
All Other Countries Lung Revenue	1.42M	1.93M
All Other Countries Lung Revenue Growth	-26.38%	51.41%
All Other Countries Heart Revenue	14.17M	13.20M
All Other Countries Heart Revenue Growth	7.36%	-5.81%
All Other Countries Liver Revenue	1.11M	158.00K
All Other Countries Liver Revenue Growth	604.43%	51.92%
All Other Countries OCS Transplant Revenue	16.70M	15.28M
All Other Countries OCS Transplant Revenue Growth	9.28%	-0.69%
Total OCS Transplant Revenue	601.40M	437.16M
Total OCS Transplant Revenue Growth	37.57%	84.66%
Other Service Revenue	4.10M	4.38M
Other Service Revenue Growth	-6.42%	-10.43%
Revenue (Total)	605.49M	441.54M
Revenue (Total) Growth	37.13%	82.74%

Revenue Breakdown 2

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 28, 2019	Dec 29, 2018	Dec 30, 2017	Dec 31, 2016
Net Product Revenue	372.40M	273.87M
Net Product Revenue Growth	35.98%	55.55%
Service Revenue	233.09M	167.67M
Service Revenue Growth	39.02%	155.78%
Revenue (Total)	605.49M	441.54M
Revenue (Total) Growth	37.13%	82.74%

Updated Dec 31, 2025. Data Source: Fiscal.ai.